TheraVet: Commercial launch of BIOCERA-VET® in the UK and Ireland

GOSSELIES, Belgium–(BUSINESS WIRE)–Regulatory news:

TheraVet (ISIN: BE0974387194 – ticker code: ALVET), pioneering company in the management of osteoarticular diseases in companion animals, announces today the commercial launch of BIOCERA-VET® – its next-generation bone substitute for bone surgery and osteosarcoma – in the UK and Ireland.

After the launches in Belgium, France and the Netherlands in 2021, TheraVet continues, as announced in its development plan, its commercial expansion strategy.

TheraVet enters the third European market with over 16 million companions (dogs and cats) in the UK. By targeting this region, TheraVet addresses a fast-growing veterinary care market with an expected CAGR of +9.5% through 20261. In 2020, the pet services market was worth £6.2 billion, of which £2.1 billion2 dedicated to veterinary care. With more than 23%3 pets covered by health insurance, the United Kingdom is one of the most covered countries behind Sweden.

To optimize its commercial deployment, the company has also launched in Ireland, a market which has around 1 million companions.

To support the launch of its products, TheraVet will attend BSAVA (British Small Animal Veterinary Association), a world-class conference in small animal veterinary medicine to be held in Manchester, UK from March 24-26, 2022. This year the conference will also be held in a hybrid format, you can attend online by registering at this link.

About TheraVet SA

TheraVet is a veterinary biotechnology company specializing in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of animals suffering from joint and bone diseases. For pet owners, the health of their pets is a top concern and TheraVet’s mission is to meet the need for innovative and curative treatments. TheraVet works closely with international opinion leaders to provide a more effective response to the ever-increasing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris and Brussels, has its head office in Belgium (Gosselies) with an American subsidiary in Texas.

For more information visit the TheraVet website

Or follow us on LinkedIn / Facebook / Twitter